Financial Statements
for the Fiscal Year Ended March 31, 2017
(From Apr. 1, 2016 to Mar. 31, 2017)

Summary of consolidated results

JMS Co., Ltd.
Company Code No. 7702

May 12, 20171

Highlights in Business Results(unit: JPY million)
Apr. - Mar. 2016
Results

Apr. - Mar. 2017
Results

Diff.

Year– over – YearSales

57,63655,574(2,061)(3.6%)

Operating Income

1,422

1,106(315)(22.2%)

Ordinary Income

1,252

1,451

199

15.9%

Profit attributable toowners of parent754

1,182427

56.7%

JPY 15.48

JPY 24.26------US Dollar

120.14108.38Euro

134.31120.33Singapore Dollar

86.70

78.26

Net Income per share
Exchange Rate(average duringperiod)(unit: JPY)

Decreased in sales, but increased inordinary Income (2nd straight year)
for the FYE Mar. 2017Japan

ProfitOverseas-Increased sales of apheresis kits
-Adverse influence of the strong yen in foreign
currency translation-Decrease in operating Income, due to the increase in depreciation
burden by the large-scale investment and R&D cost
-Increase in ordinary Income, due to the decrease in foreignexchange losses

Dividendforecast

Sales-Increased sales of Enteral nutrition system products-Increased sales of Blood bags with leukocyte
reduction filter-Annual dividend: JPY 8 per share(incl. interim dividend JYP 4 per share)

2

Sales by segment (geographical area)
Apr. – Mar. 2016

(unit: JPY million)
42,145 41,866

Sales incl. internal transaction

40,00037,233

Sales for third party

37,995
20,25920,00018,092

10,00010,389

8,929
4,158

0

Apr. – Mar. 2017

1,688

Japan

Southeast Asia

3,950
1,623

China

3,318

2,932

3,133

2,490

3,315

2,925

3,133

2,490

Germany United States

1,8751,875

1,610
1,610

Others3

Profit by segment (geographical area)
Apr. – Mar. 2017

Apr. – Mar. 2016

(unit: JPY million)
1,200
797

800

855

794

563
400

295

293
86117

93

0(73)
(400)

(800)

(388)
(642)

Japan

Southeast Asia

China

Germany United States

Others4

Summary by segment (geographical area)
Sales
Ordinary Income
Japan

Ordinary Income

797 JPY mil.

41.4%

18,092 JPY mil.

(10.7%)

794 JPY mil.

(7.2%)-Increased sales of apheresis kits for the Europe market
was offset by the decreased sales of AV fistula needles,
reducing net sales-Higher import cost with weak SGD resulted in a profit

Sales
Ordinary IncomeChina(0.7%)-Increased sales of Enteral nutrition system products wereoffset by the decreased sales of Examination Gloves,reducing net sales-Despite the increase of depreciation burden, the higher
profitability led to a profit

Sales

SoutheastAsia

41,866 JPY mil.

( %: year-over-year )3,950 JPY mil.

(5.0%)

295 JPY mil.

－%Enteral Nutrition Systems

Enteral Nutrition Systems is designed for use
when providing nutrition treatment (whichuses a tube to send nutrients directly intothe patient's body) to patients who havedifficulty absorbing nutrients throughstandard meals.

-Increased sales of Infusion Sets for Japan market was offset bydecrease in yen translation with strong yen, reducing net sales-The influence of sales increase on a local currency basis led toa profit

5Summary by segment (geographical area)
Sales
Ordinary IncomeGermany

2,932 JPY mil.

(11.6%)

86 JPY mil.

(70.4%)( %: year-over-year )-Decreased sales of Dialysis therapy chair for the Australia
market reduced net sales-Higher import cost with weak Euro resulted in a profit

Sales
Ordinary Income

2,490 JPY mil.

(20.5%)

93 JPY mil.

(20.7%)-Decreased sales of AV fistula needles for North America
market reduced net sales
United States -The influence of decreased sales resulted in a profit

AV Fistula Needle
Sales

1,610 JPY mil.

(14.1%)

Ordinary Ioss

(642) JPY mil.

－%AV fistula needle is for pulling blood from apatient during a dialysis therapy.

Others6

Sales by Business Segment
Apr. – Mar. 2016

(unit: JPY million)
30,00027,883Apr. – Mar. 201727,435

25,00020,00018,336

17,18815,00010,000
4,574

5,000

4,138

4,863

5,060
1,977

1,751

0

Infusion andTransfusion

Dialysis

General MedicalSupplies

CardiovascularOthers
7

Sales by Segment (Customer's Location)
Apr. – Mar. 2016

(unit: JPY million)
40,00036,76637,394

Apr. – Mar. 2017

Others2%

Asia・Oceania
12%Europe 9%30,000

Apr. – Mar.
2017

North America
10%

20,000Japan 67%
10,000

6,707

5,488

8,014
4,424

4,849

6,420
1,723

1,4210

Japan

North America

EuropeAsia・Oceania

Others8

Selling, General and Admin. Expenses(unit: JPY million)
15,00013,44450%
13,32912,000

30%

23.3%

24.0%

20%

10%

00%

Apr. - Mar. Apr. - Mar.
2016
2017

5,732(47)(0.8%)

1,647

1,576(71)(4.3%)

1,258

1,462

204

16.3%

412

381(30)(7.5%)

4,346

4,176(169)(3.9%)

13,444

13,329(115)(0.9%)

Apr. - Mar.
2017

Labor Cost

5,780

Transport
R&D
Depreciation
Others

3,000

Diff.

Year-overYear

Apr. - Mar.
2016

40%

9,000

6,000

(unit: JPY million)

Total9Ordinary Income: Compared with the previous year
Minus factor Plus factor
Ordinary
IncomeApr.-Mar. 2016

(unit: JPY million)

1,252
Decrease of
Gross Profit（40）
Ordinary income
increased
JPY 199 million

Increase of SGA（191）

Increase of
Non-operating profit

93337
Ordinary
IncomeApr.-Mar. 2017

Impact of
Exchange rate

1,451
The underlined figures exclude impact of exchange rate.
10Forecast for FYE Mar. 2018
(unit: JPY million)FYE Mar. 2017

FYE Mar. 2018

ResultForecast

Year-over-Year

Sales

55,57457,000

2.6%

Operating Income

1,106

1,150

3.9%

Ordinary Income

1,451

1,200(17.3%)

Profit attributable toowners of parent

1,182

700(40.8%)

JPY 24.26※ JPY 28.73---

Net Income per share
Exchange Rate (average during period)(unit: JPY)

US Dollar

108.38110.00---Euro120.33120.00---Singapore Dollar

78.26

79.00

---

※We are planning to carry out a share consolidation as to the shares of common stock of theCompany at the ratio of two (2) shares into one (1) share effective as of October 1, 2017.

11

Topics < Dec. 2016 – May. 2017 >※Announcement date-Developing new product "JMS InnerSure Ace“, Pancreaticojejunostomy assist device.
Mar. 13, 2017

-Establishing ”Dalian CDDS technical center” in China.
Feb. 20, 2017-”JMS Tongue Pressure Measuring Device” was adopted as the diagnostic criterion for“Deterioration of oral Function”.
Dec. 2, 2016

Dalian CDDS technical center

Pancreaticojejunostomy assist device"JMS InnerSure Ace"

12

The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

13